Penfluridol
Based on 11 publication(s) in Google Scholar
Penfluridol (R-16341) is a potent, long-acting, first-generation, oral diphenylbutylpiperidine antipsychotic agent by targeting D2-like dopamine receptor. Penfluridol effectively inhibits TNFα-induced NF-κB activation and alleviates the severity of arthritis and colitis in vivo. Penfluridol is a Ca2+-calmodulin inhibitor. Penfluridol induces apoptosis and autophagy. Penfluridol is used for chronic schizophrenia, acute psychosis, Tourette syndrome and autoimmune diseases. Penfluridol inhibites the growth of E. faecalis planktonic cells with the MIC of 7.81 μg/ml.
For research use only. We do not sell to patients.
- Purity : 99.84%
- CAS No.: 26864-56-2
- Formula: C28H27ClF5NO
- Molecular Weight:523.97
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
Publications Citing Use of MedChemExpress (MCE) Penfluridol
More- Adv Sci (Weinh). 2026 Jul 3:e76408. [Abstract]
- Cell Commun Signal. 2022 Jul 16;20(1):105. [Abstract]
- EMBO Mol Med. 2026 Aug;18(8):3200-3225.
- Int Immunopharmacol. 2026 Jan 1;168(Pt 2):115947. [Abstract]
- Arthritis Res Ther. 2022 Jan 19;24(1):27. [Abstract]
- Sci Rep. 2025 May 8;15(1):16114. [Abstract]
- Mediators Inflamm. 2023 Aug 22:2023:9940858. [Abstract]
- Microbiologyopen. 2021 Jan;10(1):e1148. [Abstract]
- J Ocul Pharmacol Ther. 2024 Oct;40(8):536-542. [Abstract]
- Biomed Pharmacother. 2024 Aug:177:117094. [Abstract]
- Research Square Preprint. 2021 Dec.
-
Cell Proliferation/Viability Assay
-
Cell Migration/Invasion Assay
-
Flow Cytometry
-
WB
-
Flow Cytometry
All Calcium Channel Isoforms
MoreAll Dopamine Receptor Isoforms
More
Biological Activity
Description
IC50 & Target
[2]|
D2 Receptor |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| H4 | EC50 |
3.2 μM
Compound: 2
|
Induction of autophagy in human H4 cells expressing LC3 using DAPI staining after 4 hrs by fluorescence microscopic analysis
Induction of autophagy in human H4 cells expressing LC3 using DAPI staining after 4 hrs by fluorescence microscopic analysis
|
[PMID: 21126871] |
| Lewis lung carcinoma cell line | IC50 |
4.2 μM
Compound: PFL
|
Cytotoxicity against mouse LLC cells harboring luciferin assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against mouse LLC cells harboring luciferin assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 30389290] |
| Lewis lung carcinoma cell line | IC50 |
4.3 μM
Compound: PFL
|
Cytotoxicity against mouse LLC cells harboring luciferin assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against mouse LLC cells harboring luciferin assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30389290] |
| Lewis lung carcinoma cell line | IC50 |
6 μM
Compound: PFL
|
Cytotoxicity against mouse LLC cells harboring luciferin assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against mouse LLC cells harboring luciferin assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 30389290] |
| MDA-MB-231 | IC50 |
2.3 μM
Compound: 1
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 33039722] |
| MDA-MB-231 | IC50 |
5 μM
Compound: PFL
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 30389290] |
| MDA-MB-231 | IC50 |
5.1 μM
Compound: PFL
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30389290] |
| MDA-MB-231 | IC50 |
6.1 μM
Compound: PFL
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 30389290] |
| NIH3T3 | IC50 |
6.01 μM
Compound: PFL
|
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30389290] |
| NIH3T3 | IC50 |
6.03 μM
Compound: PFL
|
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 30389290] |
| NIH3T3 | IC50 |
6.09 μM
Compound: PFL
|
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 30389290] |
| Vero | CC50 |
8.77 μM
Compound: Penfluridol
|
Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr
Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr
|
10.1101/2020.03.20.999730 |
| Vero | IC50 |
5.01 μM
Compound: Penfluridol
|
Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr
Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr
|
10.1101/2020.03.20.999730 |
In Vitro
Penfluridol (R-16341; 1.25-40 μM; 24, 48 h) reduces cell viability of human AML cells harboring FLT3-WT or the FLT3-ITD mutation[2].
Penfluridol (7.5 μM; 24 h) results in the apoptosis of AML cells harboring FLT3-WT and FLT3-ITD mutation[2].
Penfluridol (1.25-7.5 μM; 24 h) induces ROS-mediated autophagy via triggering LC3 turnover and acidic vesicular organelle (AVO) formation[2].
Penfluridol (1 μM; for 2 h) obviously inhibits TNFα-induced phosphorylation levels of ERK, JNK, and p38[3].
Penfluridol (1 μM; for 2 h) inhibits TNFα-induced mRNA expressions of IL-1β, IL-6, IL-17, and NOS2[3].
Penfluridol suppresses the differentiation of spleen naive CD4+T cells to TH1 and TH17 and inhibits M1 macrophage polarization[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Human AML cell lines, HL-60 (FLT3-WT), U937 (FLT3-WT), and MV4–11 (FLT3-ITD)
-
Concentration:1.25, 2.5, 5, 10, 20, 40 μM
-
Incubation Time:24, 48 h
-
Result:Significantly reduced cell viability in a concentration-dependent manner.
-
Cell Line:HL-60 and U937 cells harboring FLT3-WT
-
Concentration:7.5 μM
-
Incubation Time:24 h
-
Result:Induced concentration-dependent increases in the sub-G1 population.
Triggered caspase-3 activation and corresponding PARP-1 cleavage in concentration- and time-dependent manners.
-
Cell Line:U937 and HL-60 cells
-
Concentration:1.25, 2.5, 5, 7.5 μM
-
Incubation Time:24 h
-
Result:5 μM and 7.5 μM respectively induced dominant LC3B-II formation and caspase-3 activation in U937 and HL-60 cells.
-
Cell Line:BMDMs
-
Concentration:1 μM
-
Incubation Time:Pretream for 2 h
-
Result:Obviously inhibited the increased phosphorylation levels of ERK, JNK, and p38 by TNFα (10 ng/mL; 15, 30, 60 min).
-
Cell Line:BMDMs
-
Concentration:1 μM
-
Incubation Time:Pretream for 2 h
-
Result:Inhibited TNFα-induced mRNA expressions of IL-1β, IL-6, IL-17, and NOS2.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:DBA/1J male mice aged 10–12 weeks with type II chicken collagen-induced arthritis (CIA) model[3]
-
Dosage:10 mg/kg
-
Administration:Daily oral gavage; from the 18th day after the first immunization
-
Result:Inhibited inflammatory cell infiltration, suppressed pannus formation, and protected articular cartilage from damage.
obviously decreased mRNA expressions of CXCL10 and MCP-1 in inflamed joints and statistically reduced production levels of inflammatory cytokines IL-1β and IL-6 in sera.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 26864-56-2
-
Appearance Solid
-
Molecular Weight 523.97
-
Formula C28H27ClF5NO
-
Color White to off-white
-
SMILES
OC1(C2=CC=C(Cl)C(C(F)(F)F)=C2)CCN(CCCC(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)CC1
-
Synonyms
R-16341
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
Penfluridol Triggers GSDME-Mediated Immunogenic Pyroptosis to Potentiate Antitumor Immunotherapy. [Abstract]2026 Jul 3:e76408. PMID: 42396980 -
Cell Commun Signal
Inhibition of AMPK/PFKFB3 mediated glycolysis synergizes with penfluridol to suppress gallbladder cancer growth. [Abstract]2022 Jul 16;20(1):105. PMID: 35842652
Penfluridol purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2022 Jul 16;20(1):105. [Abstract]
The cell viability measured by the CCK-8 assay of SGC-996, EH-GB1, and GBC-SD cells were treated with Penfluridol (PF, 0-10 μM) as indicated for 24 h/48 h.
Penfluridol purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2022 Jul 16;20(1):105. [Abstract]
The colony formation of SGC-996, EH-GB1, and GBC-SD cells were seeded in 6-well plates and treated with Penfluridol (PF, 0-2 μM) as indicated for 14 days.
Penfluridol purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2022 Jul 16;20(1):105. [Abstract]
Annexin V/PI staining apoptosis assay of SGC-996, EH-GB1, and GBC-SD cells treated with Penfluridol (PF, 0-7.5 μM) as indicated for 24 h.
Penfluridol purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2022 Jul 16;20(1):105. [Abstract]
The Western blotting of SGC-996, EH-GB1, and GBC-SD were treated with Penfluridol (PF, 0-7.5 μM) as indicated for 24 h.
Penfluridol purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2022 Jul 16;20(1):105. [Abstract]
Cell cycle assay of SGC-996, EH-GB1, and GBC-SD cells treated with Penfluridol (PF, 0-7.5 μM) as indicated for 24 h.
-
-
Int Immunopharmacol
Dysregulated neutrophils contribute to bone loss in renal osteodystrophy by enhancing osteoclastogenesis: Insights from integrated bioinformatics and experimental validation. [Abstract]2026 Jan 1;168(Pt 2):115947. PMID: 41314047 -
Arthritis Res Ther
Penfluridol targets acid sphingomyelinase to inhibit TNF signaling and is therapeutic against inflammatory autoimmune diseases. [Abstract]2022 Jan 19;24(1):27. PMID: 35045889 -
Sci Rep
Penfluridol synergizes with colistin to reverse colistin resistance in Gram-negative bacilli. [Abstract]2025 May 8;15(1):16114. PMID: 40341530 -
Mediators Inflamm
Penfluroidol Attenuates the Imbalance of the Inflammatory Response by Repressing the Activation of the NLRP3 Inflammasome and Reduces Oxidative Stress via the Nrf2/HO-1 Signaling Pathway in LPS-Induced Macrophages. [Abstract]2023 Aug 22:2023:9940858. PMID: 37650025 -
Microbiologyopen
Drug repurposing: Antimicrobial and antibiofilm effects of penfluridol against Enterococcus faecalis. [Abstract]2021 Jan;10(1):e1148. PMID: 33345466 -
J Ocul Pharmacol Ther
2024 Oct;40(8):536-542. PMID: 39206555 -
Biomed Pharmacother
Penfluridol regulates p62 / Keap1 / Nrf2 signaling pathway to induce ferroptosis in osteosarcoma cells. [Abstract]2024 Aug:177:117094. PMID: 38996707 -
Solvent & Solubility
In Vitro:
DMSO : ≥ 100 mg/mL (190.85 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.77 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (4.77 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Collagen-Induced Arthritis
Collagen-induced arthritis (CIA) is an autoimmune murine model of rheumatoid arthritis in which immunization with type II collagen (CII) emulsified in an adjuvant induces a T cell- and autoantibody-driven inflammatory arthritis characterized by synovial hyperplasia, immune cell infiltration, and joint destruction. The model typically relies on genetically susceptible mouse strains (e. g. , DBA/1) and reproduces key features of human rheumatoid arthritis, including anti-collagen immune responses and progressive joint inflammation. Disease onset generally occurs within ~3-4 weeks after immunization, depending on antigen/adjuvant combinations and protocol variation. The immunopathology is driven by adaptive immune activation against CII, leading to systemic and local joint inflammation mediated by pro-inflammatory cytokines and effector immune cells, making CIA a standard preclinical platform for evaluating immunomodulatory and anti-arthritic interventions.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
DSS-Induced Colitis
Dextran sulfate sodium (DSS)-induced colitis is generated by administering DSS in mouse drinking water, producing epithelial injury, barrier disruption, weight loss, diarrhea, fecal blood, colon shortening, histologic mucosal damage, and inflammatory mediator changes; the model is mainly used to study acute or chronic intestinal inflammation resembling selected features of ulcerative colitis. DSS injury is interpreted through clinical and tissue readouts rather than a single molecular endpoint: daily body weight, stool consistency, and bleeding are combined into a disease activity index, while colon length, histology, cytokines, myeloperoxidase activity, intestinal permeability, and tight-junction markers provide complementary measures of inflammation and barrier damage.
-
TNBS-Induced Colitis
TNBS-induced colitis is produced by intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid in ethanol, where ethanol disrupts the mucosal barrier and TNBS haptenates colonic proteins, generating immune-mediated colonic inflammation with weight loss, diarrhea, ulceration, transmural injury, inflammatory-cell infiltration, and cytokine responses. The model is used as an experimental intestinal inflammation model with Crohn’s disease–like features, especially when Th1-type responses, IL-12–dependent inflammation, chronic relapsing inflammation, or fibrosis-related endpoints are studied.
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Ca2+ Staining Technique
Ca2+ staining is an experimental technique that utilizes specific fluorescent probes (such as Fluo-4 AM, Fura-2, etc.) to qualitatively or quantitatively detect dynamic changes in intracellular Ca2+ concentrations; this is achieved by monitoring the changes in fluorescent signals generated when these probes bind to free intracellular calcium ions. The underlying principle relies primarily on the presence of chelating groups within the probe's molecular structure that possess high affinity for calcium ions.
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Korean - KR (479 KB)
- Portuguese - PT (479 KB)
-
Handling Instructions (2659 KB)
References
[1]. Eyal Zur, et al. Penfluridol, a Unique Psychiatric Medicine for the Treatment of Chronic Schizophrenia. Int J Pharm Compd. 2019 Mar-Apr;23(2):113-119. [Content Brief]
[2]. Szu-Yuan Wu, et al. Penfluridol triggers cytoprotective autophagy and cellular apoptosis through ROS induction and activation of the PP2A-modulated MAPK pathway in acute myeloid leukemia with different FLT3 statuses. J Biomed Sci. 2019 Aug 31;26(1):63. [Content Brief]
[3]. Yue-Hong Chen, et al. Penfluridol targets acid sphingomyelinase to inhibit TNF signaling and is therapeutic against inflammatory autoimmune diseases. Arthritis Res Ther. 2022 Jan 19;24(1):27. [Content Brief]
[4]. Xianghai Zeng, et al. Drug repurposing: Antimicrobial and antibiofilm effects of penfluridol against Enterococcus faecalis. Microbiologyopen. 2021 Jan;10(1):e1148. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9085 mL | 9.5425 mL | 19.0851 mL | 47.7127 mL |
| 5 mM | 0.3817 mL | 1.9085 mL | 3.8170 mL | 9.5425 mL | |
| 10 mM | 0.1909 mL | 0.9543 mL | 1.9085 mL | 4.7713 mL | |
| 15 mM | 0.1272 mL | 0.6362 mL | 1.2723 mL | 3.1808 mL | |
| 20 mM | 0.0954 mL | 0.4771 mL | 0.9543 mL | 2.3856 mL | |
| 25 mM | 0.0763 mL | 0.3817 mL | 0.7634 mL | 1.9085 mL | |
| 30 mM | 0.0636 mL | 0.3181 mL | 0.6362 mL | 1.5904 mL | |
| 40 mM | 0.0477 mL | 0.2386 mL | 0.4771 mL | 1.1928 mL | |
| 50 mM | 0.0382 mL | 0.1909 mL | 0.3817 mL | 0.9543 mL | |
| 60 mM | 0.0318 mL | 0.1590 mL | 0.3181 mL | 0.7952 mL | |
| 80 mM | 0.0239 mL | 0.1193 mL | 0.2386 mL | 0.5964 mL | |
| 100 mM | 0.0191 mL | 0.0954 mL | 0.1909 mL | 0.4771 mL |
Keywords
- Penfluridol
- 26864-56-2
- R-16341
- R16341
- R 16341
- Calcium Channel
- Dopamine Receptor
- Autophagy
- Apoptosis
- Oral
- diphenylbutylpiperidine
- antipsychotic
- D2
- TNFα
- NF-κB
- arthritis
- colitis
- spleen naive CD4+T
- TH1
- TH17
- M1 macrophage
- chronic schizophrenia
- acute psychosis
- Tourette syndrome
- autoimmune
- E. faecalis
- planktonic
- Inhibitor
- inhibitor
- inhibit